Medical-device maker Masimo makes a product that is “the gold standard” for the industry, Chairman and CEO Joe Kiani told Cramer Tuesday on Mad Money.
When it comes to pulse oximetry, or measuring the oxygen level in blood, Masimo’s non-invasive fingertip sensor has been touted as the best by over 100 independent and objective studies, the CEO said.
And Masimo isn’t relying on just one product to fuel its growth either. Sure, pulse oximetry is a billion-dollar market, growing at 8% annually. But the analysts that cover the company say the market for all of Masimo’s products combined adds up to $2 billion to $3 billion.
Cramer likes the stock because subprime and a lagging economy can’t hurt it. He’s bullish on Masimo.
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website? firstname.lastname@example.org